Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Overall survival (reported as mortality) · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).
1 finding from 1 review
Early toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late non‐haematological toxicity ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · People with high‐risk neuroblastoma pre‐treated with autologous haematopoietic stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antiviral response ‐ 0.5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 0.5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 5mg/Kg · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level: 10 mg/kg · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 162 mg weekly · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 324 mg weekly · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 324 mg biweekly · patients being treated for HIV infection
1 finding from 1 review
Antiviral response ‐ 2mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 2 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response: 10 mg/kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 10 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 162 mg weekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 162 mg weekly compared with placebo (very low certainty).
1 finding from 1 review